远大医药

Why it is here

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — abuse of a dominant market position (市场监管总局发布远大医药与武汉汇海达成并实施垄断协议、滥用市场支配地位案行政处罚决定书), from 28 May 2023.

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — Abuse of a dominant market position.

Details

Company

远大医药

Authority

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn)

Decision

Abuse of a dominant market position

Grounds and details, as published

市场监管总局发布远大医药与武汉汇海达成并实施垄断协议、滥用市场支配地位案行政处罚决定书

From

28 May 2023

Until

—

Status

End date not published

Source

https://www.samr.gov.cn/fldys/tzgg/xzcf/art/2023/art_991d1d80a4a644aab4d15c8b998101de.html

Licence

Public antitrust decisions published by the State Administration for Market Regulation of China (samr.gov.cn/fldys)